Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Helping Skin Cells Differentiate Could Be Key to Treating Common Skin Cancer

(Penn Medicine) Aug 20, 2019 - The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow.

GO2 Foundation for Lung Cancer Partners with eHealth App Belong Beating Cancer Together to Improve Treatment Management

(Yahoo! Finance) Aug 21, 2019 - GO2 Foundation to provide patient and caregiver support and education on the world's largest social network for cancer patients.

Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis

(Yahoo! Finance) Aug 20, 2019 - Encouraging survival trends observed in patient sub-groups receiving Acelarin monotherapy informs future development in pancreatic cancer.

NIH Will Soon Share Genetic Data With Those Who Participated In Precision Medicine Study

(STAT) Aug 21, 2019 - The nearly 200,000 Americans who trusted NIH scientists with their DNA for its "All of Us" project will soon begin to receive their genetic analyses.

Updated Phase 3 Results for CT-P6 Demonstrate the Biosimilar’s Safety and Efficacy in Adjuvant Setting

(The Center For Biosimilars) Aug 21, 2019 - This week, researchers reported updated results from a post hoc subgroup analysis from the adjuvant period of treatment in the biosimilar’s phase 3 trial; these results, say the authors, demonstrate that the biosimilar, used in the adjuvant setting, has comparable efficacy and safety to the reference at 1 year.

FDA On Novartis Data Manipulation Controversy: ‘We Happened To Be Lucky’

(STAT) Aug 21, 2019 - Since the Food and Drug Administration blasted Novartis earlier this month over data manipulation, one of the major questions looming over the matter has been why the agency came down so publicly on the drug maker. The answer, according to a top FDA official, is because the stakes were too high to do otherwise.

On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer

(BioSpace) Aug 19, 2019 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent imaging agents to improve cancer surgery, announced today that it has completed its Phase 2, multi-center, open-label clinical trial for OTL38 in the detection of lung cancer nodules in lung cancer patients during surgery.

TherapeuticsMD Stock Slides 6% After SEC Charges Company With Breaking Disclosure Rules

(MarketWatch) Aug 20, 2019 - TherapeuticsMD Inc. shares slid about 6% Tuesday, after the Securities and Exchange Commission charged the company with breaching Regulation FD, or fair disclosure, for sharing material, non-public information with sell-side research analysts that was not disseminated more widely.

Update On The Phase III NEPTUNE Trial Of Imfinzi Plus Tremelimumab In Stage IV Non-Small Cell Lung Cancer

(AstraZeneca) Aug 21, 2019 - AstraZeneca today announced final overall survival (OS) results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti-CTLA4 antibody, vs. standard-of-care (SoC) platinum-based chemotherapy in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC) patients. The trial was performed in an all-comers population, and the primary analysis population was patients with a high tumour mutational burden (TMB). TMB is a measurement of the number of mutations within the genome (DNA) of a tumour, and tumours with high levels of TMB may be more visible to the immune system.1,2

Antibiotics Exposure Linked To Increased Colon Cancer Risk

(Johns Hopkins Medicine) Aug 21, 2019 - In an extensive “data mining” analysis of British medical records, researchers at the Johns Hopkins Kimmel Cancer Center conclude that taking even a single course of antibiotics might boost—albeit slightly—the risk of developing colon cancer—but not rectal cancer—a decade later.